Xenon Pharmaceuticals Inc
XENE32.555USD
+2.055+6.74%
交易中 （美东）报价延迟15分钟
2.49B总市值
亏损市盈率 TTM
关于 Xenon Pharmaceuticals Inc 公司
Xenon Pharmaceuticals Inc. 是一家总部位于加拿大的专注于神经科学的生物制药公司，致力于发现、开发和商业化治疗药物，以改善神经和精神疾病患者的生活。该公司正在推进一条新的产品线，以解决尚未得到满足的医疗需求领域，包括癫痫和抑郁症。Azetukalner 是该公司的主要 Kv7 通道开放剂，是最先进的、经过临床验证的钾通道调节剂，目前正处于多种适应症的后期临床开发阶段。Azetukalner 正在开发用于治疗癫痫，包括局灶性发作 (FOS) 和原发性全身性强直阵挛性发作 (PGTCS) 以及重度抑郁症 (MDD)。该公司正在评估针对各种适应症的多种针对 Kv7、Nav1.7 和 Nav1.1 的治疗候选药物。该公司正在与 Neurocrine Biosciences, Inc. 合作开发癫痫治疗方法。
公司简介
公司代码XENE
公司名称Xenon Pharmaceuticals Inc
上市日期Oct 17, 2014
CEOMr. Ian C. Mortimer, CPA
员工数量316
证券类型Ordinary Share
年结日Oct 17
公司地址3650 Gilmore Way
城市VANCOUVER
上市交易所NASDAQ Global Market Consolidated
国家Canada
邮编V5G 4W8
电话16044843300
网址https://www.xenon-pharma.com/
公司代码XENE
上市日期Oct 17, 2014
CEOMr. Ian C. Mortimer, CPA
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
Ms. Andrea Marie Difabio, J.D.
Ms. Andrea Marie Difabio, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Interim Chief Financial Officer, Director
President, Chief Executive Officer, Interim Chief Financial Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
收入明细
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
Canada
7.50M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 8月3日 周日
更新时间: 8月3日 周日
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
8.03%
Avoro Capital Advisors LLC
7.48%
Driehaus Capital Management, LLC
5.97%
Wellington Management Company, LLP
4.94%
Janus Henderson Investors
4.33%
Other
69.25%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
46.54%
Investment Advisor
30.34%
Hedge Fund
23.10%
Private Equity
1.66%
Venture Capital
1.05%
Sovereign Wealth Fund
0.83%
Research Firm
0.77%
Pension Fund
0.56%
Bank and Trust
0.27%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
416
84.68M
110.35%
+9.65K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
2023Q1
347
63.79M
101.12%
-4.16M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
6.16M
8.03%
+73.87K
+1.21%
Mar 31, 2025
Avoro Capital Advisors LLC
5.74M
7.48%
+75.00K
+1.32%
Mar 31, 2025
Driehaus Capital Management, LLC
4.58M
5.97%
+64.26K
+1.42%
Mar 31, 2025
Wellington Management Company, LLP
3.79M
4.94%
+11.59K
+0.31%
Mar 31, 2025
Janus Henderson Investors
3.33M
4.33%
+458.34K
+15.99%
Mar 31, 2025
Capital International Investors
3.09M
4.03%
+541.52K
+21.26%
Mar 31, 2025
Braidwell LP
2.71M
3.53%
-204.09K
-7.00%
Mar 31, 2025
Polar Capital LLP
2.62M
3.42%
-74.62K
-2.77%
Mar 31, 2025
Commodore Capital LP
2.33M
3.03%
-415.00K
-15.15%
Mar 31, 2025
Capital World Investors
2.22M
2.9%
-69.82K
-3.04%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Neuroscience and Healthcare ETF
4.34%
Tema Neuroscience and Mental Health ETF
1.82%
ALPS Medical Breakthroughs ETF
1.62%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Goldman Sachs Future Health Care Equity ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.52%
Harbor Health Care ETF
0.42%
BNY Mellon Innovators ETF
0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.34%
iShares Health Innovation Active ETF
0.34%
查看更多
iShares Neuroscience and Healthcare ETF
占比4.34%
Tema Neuroscience and Mental Health ETF
占比1.82%
ALPS Medical Breakthroughs ETF
占比1.62%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.86%
Goldman Sachs Future Health Care Equity ETF
占比0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.52%
Harbor Health Care ETF
占比0.42%
BNY Mellon Innovators ETF
占比0.35%
iShares MSCI USA Small-Cap Min Vol Factor ETF
占比0.34%
iShares Health Innovation Active ETF
占比0.34%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
